Brief: Revance Therapeutics Q1 product revenue USD 45.658 million
09/05/2023 22:36
May 9 (Reuters) - Revance Therapeutics Q1 product revenue USD 45.658 million. * Q1 operating income USD -58.032 million * Q1 operating expenses USD 107.363 million * Q1 EPS USD -0.74 * Q1 net income USD -59.793 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup